Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifampicin challenge to predict irinotecan toxicity in metastatic colorectal cancer
ACTRN12606000477527Phase 2Recruiting
- Sponsor
- Dr Nimit Singhal
- Start
- Nov 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rifampicin and irinotecan in colorectal cancer (CRC), sponsored by Dr Nimit Singhal. Primary endpoint: Rifampicin-induced hyperbilirubinemia as predictor of irinotecan toxicity. Started Nov 2006; status: recruiting.
02
Drugs
rifampicinirinotecan
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ACTRN12606000477527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12606000477527.